220 related articles for article (PubMed ID: 24727326)
1. Ganitumab (AMG 479) inhibits IGF-II-dependent ovarian cancer growth and potentiates platinum-based chemotherapy.
Beltran PJ; Calzone FJ; Mitchell P; Chung YA; Cajulis E; Moody G; Belmontes B; Li CM; Vonderfecht S; Velculescu VE; Yang G; Qi J; Slamon DJ; Konecny GE
Clin Cancer Res; 2014 Jun; 20(11):2947-58. PubMed ID: 24727326
[TBL] [Abstract][Full Text] [Related]
2. Targeting IGF-IR with ganitumab inhibits tumorigenesis and increases durability of response to androgen-deprivation therapy in VCaP prostate cancer xenografts.
Fahrenholtz CD; Beltran PJ; Burnstein KL
Mol Cancer Ther; 2013 Apr; 12(4):394-404. PubMed ID: 23348048
[TBL] [Abstract][Full Text] [Related]
3. AMG 479, a fully human anti-insulin-like growth factor receptor type I monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cells.
Beltran PJ; Mitchell P; Chung YA; Cajulis E; Lu J; Belmontes B; Ho J; Tsai MM; Zhu M; Vonderfecht S; Baserga R; Kendall R; Radinsky R; Calzone FJ
Mol Cancer Ther; 2009 May; 8(5):1095-105. PubMed ID: 19366899
[TBL] [Abstract][Full Text] [Related]
4. Epitope-specific mechanisms of IGF1R inhibition by ganitumab.
Calzone FJ; Cajulis E; Chung YA; Tsai MM; Mitchell P; Lu J; Chen C; Sun J; Radinsky R; Kendall R; Beltran PJ
PLoS One; 2013; 8(2):e55135. PubMed ID: 23383308
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of ganitumab (AMG 479), alone and in combination with rapamycin, in Ewing's and osteogenic sarcoma models.
Beltran PJ; Chung YA; Moody G; Mitchell P; Cajulis E; Vonderfecht S; Kendall R; Radinsky R; Calzone FJ
J Pharmacol Exp Ther; 2011 Jun; 337(3):644-54. PubMed ID: 21385891
[TBL] [Abstract][Full Text] [Related]
6. Results of TRIO-14, a phase II, multicenter, randomized, placebo-controlled trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-ganitumab in newly diagnosed epithelial ovarian cancer.
Konecny GE; Hendrickson AEW; Davidson TM; Winterhoff BJ; Ma S; Mahner S; Sehouli J; Fasching PA; Feisel-Schwickardi G; Poelcher M; Roman LD; Rody A; Karlan BY; Mullany SA; Chen H; Ray-Coquard IL; Provencher DM; Yachnin A; Cottu PH; Glaspy JA; Haluska P; Slamon DJ
Gynecol Oncol; 2021 Dec; 163(3):465-472. PubMed ID: 34642026
[TBL] [Abstract][Full Text] [Related]
7. Id1-induced IGF-II and its autocrine/endocrine promotion of esophageal cancer progression and chemoresistance--implications for IGF-II and IGF-IR-targeted therapy.
Li B; Tsao SW; Chan KW; Ludwig DL; Novosyadlyy R; Li YY; He QY; Cheung AL
Clin Cancer Res; 2014 May; 20(10):2651-62. PubMed ID: 24599933
[TBL] [Abstract][Full Text] [Related]
8. A novel, potent, and selective insulin-like growth factor-I receptor kinase inhibitor blocks insulin-like growth factor-I receptor signaling in vitro and inhibits insulin-like growth factor-I receptor dependent tumor growth in vivo.
Ji QS; Mulvihill MJ; Rosenfeld-Franklin M; Cooke A; Feng L; Mak G; O'Connor M; Yao Y; Pirritt C; Buck E; Eyzaguirre A; Arnold LD; Gibson NW; Pachter JA
Mol Cancer Ther; 2007 Aug; 6(8):2158-67. PubMed ID: 17671083
[TBL] [Abstract][Full Text] [Related]
9. Growth-inhibitory effects of human anti-insulin-like growth factor-I receptor antibody (A12) in an orthotopic nude mouse model of anaplastic thyroid carcinoma.
Wang Z; Chakravarty G; Kim S; Yazici YD; Younes MN; Jasser SA; Santillan AA; Bucana CD; El-Naggar AK; Myers JN
Clin Cancer Res; 2006 Aug; 12(15):4755-65. PubMed ID: 16899627
[TBL] [Abstract][Full Text] [Related]
10. Dual targeting of IGF-1R and ErbB3 as a potential therapeutic regimen for ovarian cancer.
Camblin AJ; Tan G; Curley MD; Yannatos I; Iadevaia S; Rimkunas V; Mino-Kenudson M; Bloom T; Schoeberl B; Drummond DC; Lugovskoy AA; Louis CU; Askoxylakis V
Sci Rep; 2019 Nov; 9(1):16832. PubMed ID: 31728045
[TBL] [Abstract][Full Text] [Related]
11. Insulin-like growth factor 2 silencing restores taxol sensitivity in drug resistant ovarian cancer.
Brouwer-Visser J; Lee J; McCullagh K; Cossio MJ; Wang Y; Huang GS
PLoS One; 2014; 9(6):e100165. PubMed ID: 24932685
[TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamic and antineoplastic activity of BI 836845, a fully human IGF ligand-neutralizing antibody, and mechanistic rationale for combination with rapamycin.
Friedbichler K; Hofmann MH; Kroez M; Ostermann E; Lamche HR; Koessl C; Borges E; Pollak MN; Adolf G; Adam PJ
Mol Cancer Ther; 2014 Feb; 13(2):399-409. PubMed ID: 24296829
[TBL] [Abstract][Full Text] [Related]
13. Effect of a low-fat diet combined with IGF-1 receptor blockade on 22Rv1 prostate cancer xenografts.
Konijeti R; Koyama S; Gray A; Barnard RJ; Said JW; Castor B; Elashoff D; Wan J; Beltran PJ; Calzone FJ; Cohen P; Galet C; Aronson WJ
Mol Cancer Ther; 2012 Jul; 11(7):1539-46. PubMed ID: 22562985
[TBL] [Abstract][Full Text] [Related]
14. IGF1R blockade with ganitumab results in systemic effects on the GH-IGF axis in mice.
Moody G; Beltran PJ; Mitchell P; Cajulis E; Chung YA; Hwang D; Kendall R; Radinsky R; Cohen P; Calzone FJ
J Endocrinol; 2014 Apr; 221(1):145-55. PubMed ID: 24492468
[TBL] [Abstract][Full Text] [Related]
15. IGF-1R targeting increases the antitumor effects of DNA-damaging agents in SCLC model: an opportunity to increase the efficacy of standard therapy.
Ferté C; Loriot Y; Clémenson C; Commo F; Gombos A; Bibault JE; Fumagalli I; Hamama S; Auger N; Lahon B; Chargari C; Calderaro J; Soria JC; Deutsch E
Mol Cancer Ther; 2013 Jul; 12(7):1213-22. PubMed ID: 23640142
[TBL] [Abstract][Full Text] [Related]
16. A novel calcium-dependent mechanism of acquired resistance to IGF-1 receptor inhibition in prostate cancer cells.
Fahrenholtz CD; Greene AM; Beltran PJ; Burnstein KL
Oncotarget; 2014 Oct; 5(19):9007-21. PubMed ID: 25344862
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of the IGF signaling pathway reverses cisplatin resistance in ovarian cancer cells.
Du J; Shi HR; Ren F; Wang JL; Wu QH; Li X; Zhang RT
BMC Cancer; 2017 Dec; 17(1):851. PubMed ID: 29241458
[TBL] [Abstract][Full Text] [Related]
18. Insulin-like growth factor receptor I targeting in epithelial ovarian cancer.
Gotlieb WH; Bruchim I; Gu J; Shi Y; Camirand A; Blouin MJ; Zhao Y; Pollak MN
Gynecol Oncol; 2006 Feb; 100(2):389-96. PubMed ID: 16300820
[TBL] [Abstract][Full Text] [Related]
19. Antixenograft tumor activity of a humanized anti-insulin-like growth factor-I receptor monoclonal antibody is associated with decreased AKT activation and glucose uptake.
Shang Y; Mao Y; Batson J; Scales SJ; Phillips G; Lackner MR; Totpal K; Williams S; Yang J; Tang Z; Modrusan Z; Tan C; Liang WC; Tsai SP; Vanderbilt A; Kozuka K; Hoeflich K; Tien J; Ross S; Li C; Lee SH; Song A; Wu Y; Stephan JP; Ashkenazi A; Zha J
Mol Cancer Ther; 2008 Sep; 7(9):2599-608. PubMed ID: 18790743
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of anti-insulin-like growth factor I receptor monoclonal antibody cixutumumab in mesothelioma is highly correlated with insulin growth factor-I receptor sites/cell.
Kalra N; Zhang J; Yu Y; Ho M; Merino M; Cao L; Hassan R
Int J Cancer; 2012 Nov; 131(9):2143-52. PubMed ID: 22323052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
